(STOK) Stoke Therapeutics - Ratings and Ratios

Stoke Therapeutics, Inc. (NASDAQ:STOK) is a clinical-stage biopharmaceutical company pioneering treatments for severe genetic diseases. Leveraging its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, the company designs antisense oligonucleotides to address the root causes of genetic disorders by selectively restoring protein expression. Its pipeline includes STK-001, currently in Phase I/II trials for Dravet syndrome, a rare form of epilepsy, and STK-002, in preclinical development for autosomal dominant optic atrophy, a progressive vision loss disorder. The company also explores therapies for CNS haploinsufficiency diseases. Stoke has a strategic collaboration with Acadia Pharmaceuticals to develop RNA-based treatments for rare CNS disorders. Formerly known as ASOthera Pharmaceuticals, Stoke rebranded in 2016 and operates from its headquarters in Bedford, Massachusetts. https://www.stoketherapeutics.com

Over the next three months, Stoke Therapeutics is expected to focus on advancing its clinical pipeline, particularly STK-001, as it progresses through Phase I/II trials. The company may provide updates on interim data or regulatory milestones. STK-002 remains in preclinical stages, with potential IND filing timelines a key area of focus. Collaboration with Acadia Pharmaceuticals could yield additional pipeline candidates. On the financial side, the company’s market cap of $565.69M and P/B ratio of 2.44 suggest a premium on its pipeline potential. Technically, the stock is trading below its 20-, 50-, and 200-day SMAs, indicating bearish momentum, with an ATR of 0.74 signaling moderate volatility.